How to treat fungal infections in ICU patients by unknown
Matthaiou et al. BMC Infectious Diseases  (2015) 15:205 
DOI 10.1186/s12879-015-0934-8REVIEW Open AccessHow to treat fungal infections in ICU patients
Dimitrios K Matthaiou*, Theodora Christodoulopoulou and George DimopoulosAbstract
Fungal infections represent a major burden in the critical care setting with increasing morbidity and mortality.
Candidiasis is the leading cause of such infections, with C. albicans being the most common causative agent,
followed by Aspergillosis and Mucormycosis. The diagnosis of such infections is cumbersome requiring increased
clinical vigilance and extensive laboratory testing, including radiology, cultures, biopsies and other indirect
methods. However, it is not uncommon for definitive evidence to be unavailable. Risk and host factors indicating
the probability of infections may greatly help in the diagnostic approach. Timely and adequate intervention is
important for their successful treatment. The available therapeutic armamentarium, although not very extensive,
is effective with low resistance rates for the newer antifungal agents. However, timely and prudent use is necessary to
maximize favorable outcomes.
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Fungal infections represent a major burden in the critical
care setting with increasing morbidity and mortality. Can-
dida infections, Aspergillus infections and Mucormycosis
caused by members of the Mucorales order are the most
common ones. Each one of them requires a different, al-
though similar, diagnostic and therapeutic approach. The
purpose of this review is to provide a practical guide on
the basic aspects of each of these infections in the critical
care setting.Review
Candidiasis
Candidiasis is the leading cause of fungal infections in
Intensive Care Unit (ICU) patients, with C. albicans be-
ing the most common causative agent [1,2]. Even though
Candida species is a part of the normal human flora, a
small percentage can cause disease: 1) Candidaemia with
or without endophthalmitis, 2) Disseminated haematogen-
ous infections with deep organ involvement 3) Chronic
disseminated candidiasis, most commonly found in haem-
atological patients [3,4]. Candida bloodstream infections
(BSIs) are a great proportion of nosocomial fungal infec-
tions and represent an important cause of morbidity and
mortality in ICU patients [5,6]. Additionally, the true* Correspondence: d.matthaiou@gmail.com
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unless otherwise stated.incidence of invasive candidiasis may be higher than
estimated because of the small percentage of positive
cultures obtained and the difficulty in making a diagno-
sis of invasive candidiasis without candidaemia [7,8].
There are several risk factors for the development of
invasive disease (Table 1), such as the colonization of
the gastrointestinal tract, disruption of the mucosa,
neutropenia or immunosuppression, the increased use
of medical procedures, and poor hygiene of the health
care personnel [9].
The most common pathogenic Candida spp is C.
albicans followed by C. parapsilosis, C. glabrata and C.
tropicalis. Less common pathogenic species are C. krusei,
C. dublinensis, C. guiillermondi, C. kefir, C. lusitaniae and
C. rugosa. A shift was recently observed to non-albicans
species and an expanding list of former non-pathogenic
species because of the increase in the number of vulner-
able population and the ability of isolation of new species
in the laboratory [10-12].
Undoubtedly, the early diagnosis and treatment of
invasive candidiasis is important but is often not an
easy task because of the comorbidities and the delay
in obtaining positive cultures. Candida colonization is
referred to as a risk factor for developing invasive can-
didiasis [13,14]. Several studies have presented the use
of several clinical scores by using risk factors alone or
in combination with sites of colonization in an attempt to
identify patients at risk who might benefit from antifungaltral. This is an Open Access article distributed under the terms of the Creative
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C. albicans Prolonged ICU stay, Corticosteroids, prolonged antimicrobial use, chemotherapy, immunosuppressive agents, Diabetes mellitus,
Advanced age, Central venous catheter, Gastrointestinal surgery, Total parenteral nutrition, Pancreatitis, Neutropenia, High disease
severity score (APACHE II > 20), Renal replacement therapy, Malnutrition, Multiple site colonization, Major trauma, burns over 50% of
body sites
C. glabrata Elderly, malignancies, total parenteral nutrition, central venous catheter, solid organ transplantation, antibiotics (piperacillin/tazobactam,
vancomycin), exposure to fluconazole
C. parapsilosis Second most common isolated strain in children, central venous catheter or implanted devices, total parenteral nutrition
C. tropicalis Hematological patients, neutropenia
C. krusei Hematological malignancies, neutropenia, recent gastrointestinal surgery, use of piperacillin/tazobactam, vancomycin, prior exposure
to fluconazole
C. guiillermondi Intravascular catheters
Matthaiou et al. BMC Infectious Diseases  (2015) 15:205 Page 2 of 8prophylaxis treatment. The widely used Candida
Colonization Index (CCI) defined as the ratio of the
number of culture positive surveillance sites for Can-
dida spp. over the number of sites cultured. If the CCI
is greater than 0.4 preemptive antifungal therapy
should be commenced [15]. Additionally, a recent
study presented the Candida Score (CS), which is
based on the following risk factors: surgery upon ad-
mission, total parenteral nutrition, severe sepsis and
multifocal colonization. A CS above 2.5 identifies
high-risk patients who might benefit from antifungal
prophylaxis treatment [16].Laboratory diagnosis
There are various laboratory methods aiming at early and
accurate diagnosis of invasive candidiasis. Blood cultures
have a sensitivity of up to 70%, but they have a long in-
cubation time and they are often negative in deep-sited
candidiasis and when fluconazole prophylaxis is used.
Serological tests using components of the fungal cell
wall such as galactomannan and 1,3-B-D-glucan or
antibodies against galactomannan antigen are specific
but they lack in sensitivity. Real time polymerase chain
reaction, although it has a sensitivity of 60% in diagnosing
candidemia, it is invaluable in diagnosing deep-sited
candidiasis with a negative blood culture. Lately, newer
diagnostic tools were introduced such as matrix-assisted
laser desorption ionization time of flight mass spectrom-
etry, molecular detection of fungi in blood and fluores-
cence in situ hybridization promising an accurate and
faster diagnosis [17-19]. Regarding invasive candidiasis,
antigen and antibody assays against mannan are used and
recommended by the European Society of Clinical Micro-
biology and Infectious Diseases (ESCMID) guidelines [20].
It should be noted that the MALDI-TOF currently is the
most promising method for rapid identification once a
fungal organism has been isolated.Empirical and preemptive treatment
It is difficult to recommend the early antifungal therapy
to all patients even though it may lead to improved clinical
outcomes due to increased costs, toxicity and ecological
pressure for antifungal resistance. Antifungal prophylaxis
may be useful where there are risk factors or increased
local incidence rates. Patients that may benefit from anti-
fungal prophylactic treatment with fluconazole against
invasive candidiasis are those who recently underwent
abdominal surgery and had recurrent gastrointestinal
perforations or anastomotic leakage [20]. In patients
with multifocal candida colonization who have clinical
risk factors for infection but are in stable condition,
preemptive therapy is currently not indicated. In pa-
tients with refractory fever receiving broad-spectrum
antibacterial therapy, empirical antifungal therapy may
be administered and a thorough search for alternate
causes should be performed [21].Documented candidiasis
Antifungal drugs for the treatment of candidiasis include
polyenes (amphotericin B deoxycholate, liposomal ampho-
tericin B), triazoles (fluconazole, itraconazole, voriconazole,
posaconazole), echinocandins (caspofungin, anidulafungin,
micafungin) and flucytosine (administered mostly by oral
formulation; however it is also available as intravenous for-
mulation in some countries).
Amphotericin B deoxycholate possesses fungicidal
properties by interacting with the membrane sterol, in-
creasing the permeability of the cell membrane and
allowing leakage of the fungus cell components resulting
to its death. It demonstrates high minimum inhibitory
concentrations for C. glabrata and C. kruzei and it has
got a narrow therapeutic window. Its lipid formulations
retain the activity of the parent drug, exhibit better
safety profile, but they more costly. The main adverse
events include nephrotoxicity, hepatotoxicity, anemia,




- Anidulafungin 200 mg
loading dose, then
100 mg/day
- Liposomal amphotericin B
3 mg/kg
- Caspofungin 70 mg
loading dose, then
50 mg/day
- Voriconazole 3–6 mg/kg/day
- Micafungin 100 mg - Fluconazole 400–800 mg




Stable patients - Lipid formulations of
amphotericin B 3–5 mg/kg daily -
Amphotericin B deoxycholate 0.5-
1 mg/kg daily
- Fluconazole 800 mg
loading dose, then
400 mg
Unstable patients or recent
use of fluconazole
- Anidulafungin 200 mg
loading dose, then
100 mg/day
- Voriconazole 400 mg twice
daily for 2 doses, then 200 mg
twice daily
- Caspofungin 70 mg
loading dose, then
50 mg/day
- Micafungin 100 mg/day
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sion related reactions are the most prominent and the
most frequent adverse events. The recommended dosages
are 0.5-1 mg/kg daily for amphotericin B and 3–5 mg/kg
daily for its liposomal formulations.
All triazoles are fungistatic and they inhibit cytochrome
P450 enzymes. Fluconazole has the greatest penetration
into the CSF and the vitreous body. Voriconazole is not
recommended in patients with clearance lower than
50 ml/min or under hemodialysis due to possible accumu-
lation of cyclodextrin and posaconazole is not available in
intravenous formulation and can be used in neutropenic
patients with leukemia. They interact with several drugs
increasing their concentrations (such as cyclosporine, war-
farin, tacrolimus, carbamazepine) and they also increase
also the serum levels of fentanyl and midazolam through
competitive inhibition. The recommended intravenous
dosages are a loading dose of 12 mg/kg followed by a daily
dose of 6 mg/kg for fungustatin and 2 loading doses of
6 mg/kg every 12 hours followed by 3-4 mg/kg every
12 hours for voriconazole. Dose adjustments in renal
failure should be done. Itraconazole and posaconazole,
although active against Candida, they have no label
against invasive candidiasis.
Echinocandins (caspofungin, micafungin, anidulafungin)
inhibit the synthesis of 1,3-B glucan and they are fungi-
cidal against Candida spp. The active drug is not excreted
in urine, thus they are not used in patients with candi-
duria, and it presents high MIC for C. parapsilosis. They
possess a favorable therapeutic profile with few drug in-
teractions and minor toxicity. The recommended dos-
ing regimens are a loading dose of 70 mg followed by
50 mg daily for caspofungin, a loading dose of 200 mg
followed by 100 mg daily for anidulafungin and 100 mg
daily for micafungin [22,23]. It should be noted that
caspofungin should not be used for the prophylaxis
against invasive candidiasis, as it was not found to be
superior to placebo in a recent multicenter double blind
randomized controlled trial [24].
Candida infections in the ICU may be i) suspected or
ii) documented usually by obtaining positive cultures.
i) Suspected candidiasis: if the patient has risk factors
for candida infection, prophylaxis treatment may be
initiated usually with fluconazole. Risk factors in
combination with positive serological markers may
indicate patients eligible for pre-emptive treatment.
ii) Documented candidiasis: therapy should be
commenced at the moment the blood cultures show
the growth of yeast without waiting for the species
identification and the results of susceptibility testing.
Recent ESCMID guidelines suggest the use of
echinocandins first, especially in unstable patients.
(Table 2) [20]. Current IDSA guidelines suggest theuse of fluconazole, echinocandins and amphotericin
B or its lipid formulations.
In the presence of candida infection, consecutive blood
cultures should be obtained and the length of treatment
is defined to 14 days after the last positive blood culture.
It is recommended that central venous catheters or
implanted devices (pacemakers and implantable defibrilla-
tors) should be removed and a fundoscopic examination
should be performed in order to exclude endocular infec-
tion. In the presence of localized candidiasis the suggested
treatment, according to IDSA guidelines, is presented in
Table 3 [25].
Aspergillosis
Aspergillus is a fungal genus encompassing hundreds of
molds, the most clinically important of which are A.
fumigatus, A. flavus, A. terreus, A. niger, and A. nidulans.
Recently, Neosartorya udagawae has also emerged with
increased clinical impact [26,27]. It has a wide environ-
mental distribution, it may be found in the soil, water, air
and decomposing organic matter, and may colonize or
cause infection mostly in immunocompromised patients.
Epidemiology, incidence and outcomes
In the critical care setting, Aspergillus may harbor in the
ICU ventilation and water systems that have been poorly
maintained, as well as in various equipment. However, there
is a difficulty in discriminating between colonization and
infection when they are isolated from the patient. Incidence
Table 3 Treatment of localized candidiasis
Primary therapy Alternative therapy
Pyelonephritis Fluconazole 200–400 mg for 14 days Amphotericin B deoxycholate 0.5-0.7 mg/kg daily +/− flucytosine
25 mg/kg four times daily or flucytosine alone for 14 days
Osteomyelitis Fluconazole 400 mg daily for 6–12 months Echinocandin* or Amphotericin B deoxycholate 0.5-1 mg/kg
daily for several weeks and then fluconazole for 6–12 months
Lipid formulations of amphotericin B 3–5 mg/kg daily for several
weeks, then fluconazole for 6–12 months
Septic arthritis Fluconazole 400 mg daily for at least 6 weeks Echinocandin* or Amphotericin B deoxycholate 0.5-1 mg/kg
daily for several weeks and then fluconazole
Lipid formulations of amphotericin B 3–5 mg/kg daily for several
weeks, then followed by fluconazole
CNS candidiasis Lipid formulations of amphotericin B 3–5 mg/kg +/− flucytosine
25 mg/kg four times daily for several weeks, followed by
fluconazole 400–800 mg daily until the resolution of symptoms
Fluconazole 400–800 mg daily for patients intolerant to lipid
formulations of amphotericin B
Endophthalmitis Amphotericin B deoxycholate 0.7-1 mg/kg with flucytosine
25 mg/kg four times daily for at least 4–6 weeks along with
surgical intervention for severe cases
Lipid formulations of amphotericin B 3–5 mg/kg daily
Voriconazole 6 mg/kg twice daily for two doses, then 3–4 mg/kg
twice daily
Echinocandin*
Endocarditis Lipid formulations of amphotericin B 3–5 mg/kg +/− flucytosine
25 mg/kg four times daily
Valve replacement is strongly recommended, otherwise chronic
suppression with fluconazole 400–800 mg daily is recommended.
Lifelong suppressive therapy for prosthetic valve endocarditis if
valve cannot be replaced is recommended.Amphotericin B deoxycholate 0.6-1 mg/kg +/− flucytosine
25 mg/kg four times daily
Echinocandin**
*Anidulafungin 200 mg loading dose, then 100 mg/day; Caspofungin 70 mg loading dose, then 50 mg/day; Micafungin 100 mg/day.
**For endocarditis higher doses of echinocandins may be required such as Anidulafungin 100–200 mg/day; Caspofungin 50–150 mg/day;
Micafungin 100–150 mg/day.
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Virtually any organ may be affected by Aspergillus species,
with sinopulmonary involvement as invasive pulmonary
aspergillosis being the most common [28]. The lowest
incidence for invasive aspergillosis (IA) is reported in
patients with HIV and in patients with hematologic ma-
lignancy, which is 0.4% [29]. The incidence in patients
with solid organ transplants vary from 0.1 to 2.4%,
while in patients with stem cell transplants, vary from
0.5 to 3.8% [30]. In patients with hematopoietic stem
cell transplantation incidence rates are about 5% for
autologous and 5-10% for allogeneic transplantation,
respectively [31,32].
Mortality rates also vary. The overall mortality rates of
Aspergillosis are about 17%, based on US national data,
but mortality is higher in cases of Aspergillus pneumonia
and in immunocompromised patients with IA [33]. Specif-
ically, in Aspergillus pneumonia mortality rises to 25%,
while in patients with blood and lymphoid tissue malig-
nancies, bone marrow transplant recipients, and liver
transplant recipients, mortality rates of IA are 49%, 80%,
and 90%, respectively [33,34].
It should be noted that the immune status of critically
ill patients, as well as other underlying conditions, are
important determinants of the type of fungal infection they
may develop and it is usually of the invasive form. Thus,
patients receiving steroids are in increased risk of having
cavitating lesions and aspergillomas, and neutropenicpatients develop angioinvasive aspergillosis, as neutrophils
play a major role in the clearance of Aspergillus [35,36].
Patients who received lung transplantation are often colo-
nized with Aspergillus due to their primary lung disease
[37] and are more likely to present with aspergillosis
around the anastomoses [38]. Also, involvement of other
foci including endocarditis and osteomyelitis has been
reported [39,40].
Risk factors
Neutropenia was the first risk factor to be recognized
for invasive aspergillosis more than forty years ago [41].
The absolute neutrophil number per se is not the sole
determinant, as the overall neutrophil functional status
plays a major role in the pathogenesis of Aspergillus.
However, one should keep in mind that neutropenia and
compromised immune functional status usually concur
in several conditions.
Following this rough categorization, common neutro-
penic conditions that may lead to the development of
invasive aspergillosis are hematologic malignancies and
myeloablative chemotherapy in stem cell recipients
[42]. Prolonged duration and degree of neutropenia are
important factors of developing the disease. Solid organ
transplantation recipients, especially of lung, are at in-
creased risk for invasive aspergillosis, as they receive
immunosuppressive therapy and are subjected to envir-
onmental exposure to Aspergillus.
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functionality, steroid therapy is a major risk factor as it may
be administered either as anti-inflammatory drug in the
course of infections or as immunosuppressive treatment
during transplantations [43-46]. Other similar conditions
associated with invasive aspergillosis are prior antibiotic
treatment, AIDS, H1N1 infection, chronic obstructive
pulmonary disease, chronic granulomatous disease, and
acute renal failure [43,44,47-50]. It is interesting that
patients receiving immuno-modulatory drugs, namely
TNF-a inhibitors, are also at increased risk for invasive
aspergillosis [51].
Diagnosis
The diagnosis is based on a triplet consisting of (i) risk
and host factors (the latter not being identical to risk
factors), (ii) clinical and radiological signs and symptoms
that are indicative of the disease and (iii) laboratory testing
that proves the existence of Aspergillus either directly or
indirectly.
According to the definitions published by the European
Organization for Research and Treatment of Cancer/My-
cosis Study Group (EORTC/MSG), the utilization of these
criteria classify the diagnosis of invasive aspergillosis in
proven, probable and possible [52]. For a proven infection,
it is required to have a positive culture of an otherwise
sterile site or a positive histopathologic or cytopathologic
examination. It should be noted that, although very useful
in the diagnostic process, clinical symptoms and signs and
risk and host factors are not mandatory when the presence
of Aspergillus has been demonstrated. For a probable
infection, all elements of the aforementioned triplet are
required to be positive. However, mycological evidence
retrieved from various sites not essentially sterile may be
used including bronchoalveolar lavage, bronchial speci-
mens retrieved with brush, sinus aspirates, sputum etc.
For a possible infection, a diagnosis can be done when
there are appropriate risk/host factors and clinical symp-
toms and signs, but mycological evidence is lacking.
It should be noted that these definitions were based
on the study of immunosuppressed patient. As such,
they may not be fully applicable in critically ill patients,
who are a different population, although immunosup-
pressed patients may represent a subset of them. It has
been supported that the presence of Aspergillus in that
patient setting, irrespective of infection or colonization,
indicates a poor prognostic marker [53]. The use of
appropriate clinical algorithms may offer further aid in
diagnosing invasive aspergillosis and discriminating
between infection and colonization with relatively high
sensitivity and specificity [54].
The radiological tests that may be used are chest x-
rays and CT scanning. The most common signs that
may be found are consolidations, and infiltrates andnodules [55]. However, the pathognomonic sign is the
“halo sign”, which is found in CT scans as a nodule with a
dense center surrounded by ground glass opacity. It
should be noted that the latter is mostly found in neutro-
penic patients, while relevant findings of non-neutropenic
patients are nonspecific [56].
Laboratory testing used for the detection of Aspergillus
includes biopsies, cultures, detection of galactomannan
and β-D-glucan and PCR. As noted before, the isolation of
Aspergillus from cultures depends on whether the site of
isolation is otherwise sterile, since a positive culture from
respiratory tract secretions, irrespective of the method
used for isolation, may represent colonization rather than
infection [57]. Galactomannan is detected in body fluids
and depending on its concentration galactomannan index
is calculated. When a certain threshold is surpassed, then
a diagnosis of invasive aspergillosis is likely. Although the
sensitivity of the method in the serum is limited [58], it
seems that galactomannan detection in bronchoscopic
material, such as bronchoalveolar lavage, has superior
accuracy and is not affected by the immune status of the
patient [59]. β-D-glucan is, like galactomannan, a cell wall
component, which is also found in body fluids and its
presence indicates the probability of infection. PCR, al-
though it is a method with high sensitivity and specificity,
is cumbersome and lacks in discrimination power between
colonization and infection [60,61]. Quantitative real time
PCR may pose as a useful alternative in the diagnosis of
invasive aspergillosis [62].
Treatment
Treatment of aspergillosis may be classified in empirical,
preemptive and definitive. Empirical treatment is the
one administered to neutropenic patients at risk with a
prolonged febrile period, who have already received
broad antibiotic coverage. Preemptive therapy is the one
administered when there is evidence of fungal existence
without a developed infection. However, its benefit has
been questioned compared to empirical treatment [63].
Definitive treatment is the one administered when infection
has developed and it is based on antibiogram data. When
definitive treatment with a single agent is not successful,
combination treatment may be used in the salvage setting
[64]. Prophylactic treatment, although administered in neu-
tropenic patients, has not found its place in the critical care
setting. Adjunctive therapies including Granulocyte-Colony
Stimulating Factor and interferon-gamma may be used.
Surgical treatment for the resection of Aspergillus lesion
may be an alternative option in selected cases [65].
Although amphotericin B, azoles and echinocandins
may be used for the treatment of Aspergillosis, voriconazole
is considered as the first line treatment, especially for the
invasive pulmonary form. It is administered intravenously
in a dosage of 6 mg/kg twice daily as a loading dose and
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Amphotericin B is administered intravenously as liposomal
amphotericin in a dosage of 3 to 5 mg/kg/day or as its lipid
complex in a dosage of 5 mg/kg/day, but has lost its pre-
dominance due to the nephrotoxicity it may confer and the
newer therapeutic alternatives that have been found [66]. A
paradox regarding its reduced toxicity when administered
in high doses, although without a subsequent improvement
in outcomes, should be noted [67]. From the echinocandin
class, only caspofungin has been approved for the treat-
ment of Aspergillosis, but is used when treatment with
other agents is not successful or not allowed due to adverse
events. It is used mostly when other antifungals have failed
and it is administered in combination with amphotericin
[68]. It is administered intravenously in a dosage of 70 mg/
day as a loading dose and 50 mg/day thereafter [66]. When
administered in combination with calcineurin pathway
inhibitors, it was found to have increased in vitro activity
[69]. Itraconazole and posaconazole is considered second-
line treatment option. Posaconazole has been approved as
salvage treatment of invasive aspergillosis in the European
Union only.
The duration of treatment varies depending on the
patient’s immune status. In non-immunosuppressed pa-
tients it should last for a minimum of 6 to 12 weeks. In
immunosuppressed patients, treatment should be ad-
ministered as long as the patient is immunosuppressed
and should not be stopped until the clinical and radio-
logical resolution of symptoms and signs. Laboratory
testing to certify the eradication of the fungus is not
suggested. Relapses due to incomplete eradication and
lack of sterilization of underlying foci may occur.
Mucormycosis
Mucorales are saprophytes causing a disease known as
mucormycosis. The most common genera include Rhizo-
pus, Mucor and Rhizomucor. Risk factors in the critical
care setting include neutropenia, diabetes, malignancy,
desferoxamine therapy, renal failure, hematopoietic stem
cell transplantation and penetrating trauma [70]. Mortality
is high ranging from 35% when no underlying condition is
present to 66% in patients with malignancy.
Methods for the diagnosis of mucormycosis are limited.
Practically, the sole approach that may provide evidence
of Mucorales presence is through histopathology using
hematoxylin-eosin, Grocott-methanamine-silver and peri-
odic acid-Schiff stains. PCR use has also been described,
but it is not routinely used. Radiological testing rarely pro-
vides specific findings [71].
Treatment options are also limited. The mainstay of
treatment is amphotericin B in its deoxycholate, lipid
complex or liposomal form. The respective dosages are 1 to
1.5 mg/kg/day, 5 to 7.5 mg/kg/day and 5 to 10 mg/kg/day.
It should be noted that the deoxycholate form, althoughthe most toxic and with the poorest penetration in the
central nervous system, is the only formulation ap-
proved for the treatment of mucormycosis. Limited
data regarding combination treatment of lipid ampho-
tericin with echinocandins are also available [72]. The
combination of deferasirox with lipid amphotericin was
found to be highly fungicidal in animal models [73].
However, a recent small phase II trial found that pa-
tients with mucormycosis treated with deferasirox had
a higher mortality rate at 90 days and did not support a
role for initial, adjunctive deferasirox therapy for
mucormycosis [74]. Surgical debridement may also be
used as adjunctive therapy [75].
The duration of treatment for mucormycosis is not
established and should be individualized for each patient.
It should be continued until there is resolution of clinical
signs and symptoms, radiological findings, if any, and of
immunosuppression.
Conclusions
Fungal infections, although of great importance, are not
easy to diagnose and treat in the critical care setting. To
limit the mortality toll of such infections, increased clinical
vigilance and a multifaceted diagnostic approach is
mandatory. The therapeutic armamentarium, although not
very extensive, is effective with low resistance rates for the
newer antifungal agents. However, timely and prudent use
is necessary to maximize favorable outcomes.
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